Moderna to Report Q1 2026 Financial Results

The biotech firm will host a live webcast to discuss its quarterly performance and provide a corporate update.

Apr. 15, 2026 at 1:08pm

Got story updates? Submit your updates here. ›

An extreme close-up of a tangle of gears, wires, and mechanical components, conceptually representing the intricate financial and technological infrastructure supporting Moderna's mRNA platform.Moderna's advanced mRNA technology powers the company's innovative pipeline of vaccines and therapeutics, as seen in this close-up of the complex financial and operational machinery behind its success.Cambridge Today

Moderna, Inc. announced that it will host a live conference call and webcast on Friday, May 1, 2026 to report its first quarter 2026 financial results and provide a corporate update. The webcast will be available on Moderna's website approximately two hours after the call and will be accessible for one year.

Why it matters

As a pioneer in mRNA technology, Moderna's quarterly financial performance and business updates are closely watched by investors and the broader healthcare industry. The company's ability to continue advancing its mRNA platform across various disease areas could have significant implications for the future of medicine.

The details

Moderna will host the live conference call and webcast at 8:00 a.m. ET on May 1, 2026 to discuss its Q1 2026 financial results. The archived webcast will be available on the company's website shortly after the call and remain accessible for one year.

  • Moderna will host the live conference call and webcast on Friday, May 1, 2026 at 8:00 a.m. ET.
  • The archived webcast will be available on Moderna's website approximately two hours after the conference call.

The players

Moderna, Inc.

A pioneer and leader in the field of mRNA medicine, developing vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

Got photos? Submit your photos here. ›

The takeaway

Moderna's upcoming financial report and corporate update will provide valuable insights into the company's progress in advancing its mRNA platform and the potential impact of its medicines on the future of healthcare.